Ewing/Ewing-like Sarcoma, Liposarcoma, Mesenchymal Chondrosarcoma, Osteogenic Sarcoma, Rhabdomyosarcoma
Conditions
Brief summary
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.
Detailed description
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents
Interventions
DRUGRegorafenib
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
DRUGPlacebo
21 days on and 7 days off
Sponsors
Sarcoma Alliance for Research through Collaboration
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 10 year for Liposarcoma, Osteosarcoma, Ewing sarcoma and Mesenchymal Chondrosarcoma; Age ≥ 5 years for Rhabdomyosarcoma cohorts * Weight ≥ 15 kg (33 lb) * Patients must have histologically or cytologically confirmed advanced/metastatic liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcoma of soft tissue or bone, fusion-positive alveolar rhabdomyosarcoma or embryonal rhabdomyosarcoma/fusion-negative alveolar rhabdomyosarcoma , or mesenchymal chondrosarcoma * WHO Performance Status 0, 1 or 2. A maximum of 1/3 of patients in cohorts A & B may be WHO performance status 2 * At least one prior line of systemic therapy for the sarcoma diagnosis (neoadjuvant, adjuvant or metastatic disease) * All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v 4.0 Grade 1 or less (except alopecia) at the time of signing the Informed Consent Form (ICF) * Subject must be able to swallow and retain oral medication * At least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST 1.1 * Adequate organ function within 14 days of registration * Written, voluntary informed consent * Fertile men and women of childbearing potential must agree to use an effective method of birth control from Day 1 of study and for 3 months after last study drug administration in both sexes, as assessed by the investigator. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test less than or equal to seven days prior to Day 1 of study. The definition of adequate contraception will be based on the judgement of the investigator. * Evidence of progression of disease as defined by RECIST 1.1 (i.e. new disease sites or 20% growth of index lesions) within 6 months of registration * Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least 12 weeks after therapy
Exclusion criteria
* Patients with documentation of well differentiated liposarcoma only (of the well differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing to its characteristically slow growth. If high grade areas are suspected (dedifferentiation), but not proved by pathology analysis (e.g. after primary resection of a well-differentiated liposarcoma), a biopsy must be performed to demonstrate the high-grade dedifferentiated disease * Prior systemic therapy with a small molecule oral kinase inhibitor, including but not limited to: pazopanib, sunitinib, sorafenib, everolimus, sirolimus, vemurafenib, dasatinib and trametinib * Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study. Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteria * Concurrent, clinically significant, active malignancies within 12 months of study enrollment * Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol * Major surgery within 28 days prior to study registration or those patients who have not recovered adequately from prior surgery * Patients who have received wide field radiotherapy ≤ 28 days (defined as \> 50% of volume of pelvis bones or equivalent) or limited field radiation for palliation \< 14 days prior to study registration or those patients who have not recovered adequately from side effects of such therapy * Patients who have received prior systemic therapy \< 14 days prior to study registration or have not recovered adequately from toxicities to CTCAE v. 4.03 grade 1 or less; prior investigational therapy may not have been given \< 5 half-lives of last dose of treatment, or \< 14 days, whichever is greater * Patients who have had prior autologous, or allogeneic bone marrow transplant * Uncontrolled hypertension (systolic pressure \>140 mm Hg or diastolic pressure \> 90 mm Hg \[NCI-CTCAE v 4.0\] on repeated measurement) despite optimal medical management * Active or clinically significant cardiac disease including: Congestive heart failure-New York Heart Association (NYHA) \> class II, Active coronary artery disease, Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, Unstable angina (anginal symptoms at rest), new onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization * Evidence or history of bleeding diathesis * Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to study registration * Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment * Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy. * Ongoing infection \> Grade 2 NCI-CTCAE v 4.03 * Presence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients with stress insufficiency fractures e.g. from osteoporosis or pathological fracture from tumor are eligible for study) * Patients with seizure disorder requiring medication * Proteinuria \> 100 mg/dl on urine analysis * Interstitial lung disease with ongoing signs and symptoms at the time of informed consent * Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version 4.03 Grade 2 dyspnea) * History of organ allograft (including corneal transplant). * Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial * Any malabsorption condition. * Women who are pregnant or breast-feeding. * Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation * Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results * Inability to comply with protocol required procedures * Use of any herbal remedy (e.g. St. John wort \[Hypericum perforatum\])
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS). Cohort A and Cohort B | up to 3 years | The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort A (liposarcoma) and Cohort B (osteosarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1, where a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
| Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E | up to 16 weeks | The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort C (Ewing/Ewing-like sarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS), Cohorts A and B, After Crossover. | up to 3 years | The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. |
| Response Rate (RR), Cohorts A and B, After Crossover. | up to 3 years | The response rate (RR) is the percentage of patients whose cancer shrinks or disappears after treatment. |
| The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | up to 3 years | Common Toxicity Criteria, also referred to as the Common Terminology Criteria for Adverse Events (CTCAE), is a standardized classification of side effects used in assessing drugs for cancer therapy. Cohorts A, B, C, and D. |
| Overall Survival (OS). Cohorts A and B, After Crossover. | up to 3 years | Overall survival (OS) is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. |
| Disease Specific Survival (DSS). Cohorts A and B, After Crossover. | up to 3 years | Disease-specific survival refers to the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time. |
| Time to Tumor Progression (TTP), Cohorts A and B, After Crossover. | up to 3 years | Time to tumor progression (TTP) is the length of time from the date of diagnosis or the start of treatment for a disease until the disease starts to get worse or spread to other parts of the body. |
| Overall Response Rate (ORR). All Cohorts. | up to 3 years | The overall response rate (ORR) is the percentage of patients whose cancer shrinks or disappears after treatment. ORR will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 |
Countries
United States
Participant flow
Pre-assignment details
Study enrollment ended early due to slow enrollment.
Participants by arm
| Arm | Count |
|---|---|
| Cohort A: Liposarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Regorafenib
Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off | 24 |
| Cohort A: Liposarcoma, Placebo 21 days on and 7 days off
Placebo
Placebo: 21 days on and 7 days off | 24 |
| Cohort B: Osteosarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Regorafenib
Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off | 22 |
| Cohort B: Osteosarcoma, Placebo 21 days on and 7 days off
Placebo
Placebo: 21 days on and 7 days off | 20 |
| Cohort C: Ewing Sarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Regorafenib
Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off | 30 |
| Cohort D: Rhabdomyosarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Regorafenib
Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off | 10 |
| Cohort E: Mesenchymal Chondrosarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Regorafenib
Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off | 1 |
| Total | 131 |
Baseline characteristics
| Characteristic | Cohort A: Liposarcoma | Cohort A: Liposarcoma, Placebo | Cohort B: Osteosarcoma | Cohort B: Osteosarcoma, Placebo | Cohort C: Ewing Sarcoma | Cohort D: Rhabdomyosarcoma | Cohort E: Mesenchymal Chondrosarcoma | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 4 Participants | 0 Participants | 4 Participants |
| Age, Categorical >=65 years | 7 Participants | 12 Participants | 1 Participants | 4 Participants | 1 Participants | 0 Participants | 0 Participants | 25 Participants |
| Age, Categorical Between 18 and 65 years | 17 Participants | 12 Participants | 21 Participants | 16 Participants | 29 Participants | 6 Participants | 1 Participants | 102 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 4 Participants | 2 Participants | 1 Participants | 2 Participants | 0 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 23 Participants | 22 Participants | 17 Participants | 17 Participants | 28 Participants | 6 Participants | 1 Participants | 114 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 0 Participants | 7 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 3 Participants | 2 Participants | 3 Participants | 2 Participants | 1 Participants | 0 Participants | 11 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 1 Participants | 5 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 7 Participants |
| Race (NIH/OMB) White | 16 Participants | 20 Participants | 12 Participants | 15 Participants | 27 Participants | 8 Participants | 1 Participants | 99 Participants |
| Sex: Female, Male Female | 14 Participants | 6 Participants | 16 Participants | 6 Participants | 10 Participants | 5 Participants | 0 Participants | 57 Participants |
| Sex: Female, Male Male | 10 Participants | 18 Participants | 6 Participants | 14 Participants | 20 Participants | 5 Participants | 1 Participants | 74 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 25 / 39 | 7 / 9 | 26 / 33 | 8 / 9 | 17 / 30 | 4 / 6 | 2 / 4 | 0 / 1 |
| other Total, other adverse events | 26 / 39 | 8 / 9 | 26 / 33 | 6 / 9 | 22 / 30 | 2 / 6 | 1 / 4 | 0 / 1 |
| serious Total, serious adverse events | 28 / 39 | 7 / 9 | 24 / 33 | 7 / 9 | 21 / 30 | 4 / 6 | 2 / 4 | 0 / 1 |
Outcome results
Primary
Progression-free Survival (PFS). Cohort A and Cohort B
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort A (liposarcoma) and Cohort B (osteosarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1, where a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: up to 3 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Liposarcoma | Progression-free Survival (PFS). Cohort A and Cohort B | 1.87 months |
| Cohort A: Liposarcoma, Placebo | Progression-free Survival (PFS). Cohort A and Cohort B | 2.07 months |
| Cohort B: Osteosarcoma | Progression-free Survival (PFS). Cohort A and Cohort B | 3.6 months |
| Cohort B: Osteosarcoma, Placebo | Progression-free Survival (PFS). Cohort A and Cohort B | 1.7 months |
Primary
Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort C (Ewing/Ewing-like sarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
Time frame: up to 16 weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Liposarcoma | Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E | 3.4 months |
| Cohort A: Liposarcoma, Placebo | Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E | 1.82 months |
| Cohort B: Osteosarcoma | Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E | NA months |
Secondary
Disease Specific Survival (DSS). Cohorts A and B, After Crossover.
Disease-specific survival refers to the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time.
Time frame: up to 3 years
Population: Participants who started on placebo and crossed over to active drug upon progression.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Liposarcoma | Disease Specific Survival (DSS). Cohorts A and B, After Crossover. | 7.98 months |
| Cohort A: Liposarcoma, Placebo | Disease Specific Survival (DSS). Cohorts A and B, After Crossover. | 16.11 months |
Secondary
Overall Response Rate (ORR). All Cohorts.
The overall response rate (ORR) is the percentage of patients whose cancer shrinks or disappears after treatment. ORR will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1
Time frame: up to 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A: Liposarcoma | Overall Response Rate (ORR). All Cohorts. | 0 Participants |
| Cohort A: Liposarcoma, Placebo | Overall Response Rate (ORR). All Cohorts. | 1 Participants |
| Cohort B: Osteosarcoma | Overall Response Rate (ORR). All Cohorts. | 3 Participants |
| Cohort B: Osteosarcoma, Placebo | Overall Response Rate (ORR). All Cohorts. | 0 Participants |
| Cohort C: Ewing Sarcoma | Overall Response Rate (ORR). All Cohorts. | 3 Participants |
| Cohort D: Rhabdomyosarcoma | Overall Response Rate (ORR). All Cohorts. | 0 Participants |
| Cohort E: Mesenchymal Chondrosarcoma | Overall Response Rate (ORR). All Cohorts. | 0 Participants |
Secondary
Overall Survival (OS). Cohorts A and B, After Crossover.
Overall survival (OS) is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
Time frame: up to 3 years
Population: Participants who started on placebo and crossed over to active drug after progression.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Liposarcoma | Overall Survival (OS). Cohorts A and B, After Crossover. | 7.98 months |
| Cohort A: Liposarcoma, Placebo | Overall Survival (OS). Cohorts A and B, After Crossover. | 16.11 months |
Secondary
Progression-free Survival (PFS), Cohorts A and B, After Crossover.
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Time frame: up to 3 years
Population: Participants who started on placebo in Cohorts A and B, then crossed over to active drug after progression.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Liposarcoma | Progression-free Survival (PFS), Cohorts A and B, After Crossover. | 1.68 months |
| Cohort A: Liposarcoma, Placebo | Progression-free Survival (PFS), Cohorts A and B, After Crossover. | 5.78 months |
Secondary
Response Rate (RR), Cohorts A and B, After Crossover.
The response rate (RR) is the percentage of patients whose cancer shrinks or disappears after treatment.
Time frame: up to 3 years
Population: Participants who started on placebo then crossed over to active drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A: Liposarcoma | Response Rate (RR), Cohorts A and B, After Crossover. | 0 Participants |
| Cohort A: Liposarcoma, Placebo | Response Rate (RR), Cohorts A and B, After Crossover. | 0 Participants |
Secondary
The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts.
Common Toxicity Criteria, also referred to as the Common Terminology Criteria for Adverse Events (CTCAE), is a standardized classification of side effects used in assessing drugs for cancer therapy. Cohorts A, B, C, and D.
Time frame: up to 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort A: Liposarcoma | The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | 12 Participants |
| Cohort A: Liposarcoma, Placebo | The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | 15 Participants |
| Cohort B: Osteosarcoma | The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | 6 Participants |
| Cohort B: Osteosarcoma, Placebo | The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | 9 Participants |
| Cohort C: Ewing Sarcoma | The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | 6 Participants |
| Cohort D: Rhabdomyosarcoma | The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | 2 Participants |
| Cohort E: Mesenchymal Chondrosarcoma | The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts. | 0 Participants |
Secondary
Time to Tumor Progression (TTP), Cohorts A and B, After Crossover.
Time to tumor progression (TTP) is the length of time from the date of diagnosis or the start of treatment for a disease until the disease starts to get worse or spread to other parts of the body.
Time frame: up to 3 years
Population: Participants who crossed over to active drug after placebo.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Liposarcoma | Time to Tumor Progression (TTP), Cohorts A and B, After Crossover. | 1.76 months |
| Cohort A: Liposarcoma, Placebo | Time to Tumor Progression (TTP), Cohorts A and B, After Crossover. | 5.78 months |